KR101952457B1 - [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그 - Google Patents

[3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그 Download PDF

Info

Publication number
KR101952457B1
KR101952457B1 KR1020137009506A KR20137009506A KR101952457B1 KR 101952457 B1 KR101952457 B1 KR 101952457B1 KR 1020137009506 A KR1020137009506 A KR 1020137009506A KR 20137009506 A KR20137009506 A KR 20137009506A KR 101952457 B1 KR101952457 B1 KR 101952457B1
Authority
KR
South Korea
Prior art keywords
methyl
ethyl
imidazol
benzyl ester
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137009506A
Other languages
English (en)
Korean (ko)
Other versions
KR20130105658A (ko
Inventor
켄 차우
모하메드 아이. 디바스
존 이. 도넬로
마이클 이. 가스트
다니엘 더블유. 길
리밍 왕
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101952457(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20130105658A publication Critical patent/KR20130105658A/ko
Application granted granted Critical
Publication of KR101952457B1 publication Critical patent/KR101952457B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137009506A 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그 Active KR101952457B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
US61/383,370 2010-09-16
PCT/US2011/052004 WO2012037499A1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197004880A Division KR102104760B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그

Publications (2)

Publication Number Publication Date
KR20130105658A KR20130105658A (ko) 2013-09-25
KR101952457B1 true KR101952457B1 (ko) 2019-02-26

Family

ID=44675870

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020137009506A Active KR101952457B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009503A Active KR101840501B1 (ko) 2010-09-16 2011-09-16 망막 질환을 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009505A Withdrawn KR20140005154A (ko) 2010-09-16 2011-09-16 피부 질환과 장애를 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020207021626A Active KR102354097B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020197004880A Active KR102104760B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009502A Active KR101840500B1 (ko) 2010-09-16 2011-09-16 안압을 낮추기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020207011231A Active KR102139905B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그

Family Applications After (6)

Application Number Title Priority Date Filing Date
KR1020137009503A Active KR101840501B1 (ko) 2010-09-16 2011-09-16 망막 질환을 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009505A Withdrawn KR20140005154A (ko) 2010-09-16 2011-09-16 피부 질환과 장애를 치료하기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020207021626A Active KR102354097B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020197004880A Active KR102104760B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020137009502A Active KR101840500B1 (ko) 2010-09-16 2011-09-16 안압을 낮추기 위한 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR1020207011231A Active KR102139905B1 (ko) 2010-09-16 2011-09-16 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그

Country Status (28)

Country Link
US (9) US8492557B2 (https=)
EP (13) EP3050564B1 (https=)
JP (4) JP2013541527A (https=)
KR (7) KR101952457B1 (https=)
CN (5) CN103209694A (https=)
AR (4) AR083018A1 (https=)
AU (4) AU2011301932C1 (https=)
BR (4) BR112013006362A2 (https=)
CA (8) CA2812191C (https=)
CL (4) CL2013000735A1 (https=)
CY (3) CY1121024T1 (https=)
DK (9) DK2616068T3 (https=)
ES (10) ES2607084T3 (https=)
HU (5) HUE047476T2 (https=)
IL (4) IL225280A0 (https=)
MX (4) MX2013003004A (https=)
MY (4) MY161607A (https=)
NZ (1) NZ608751A (https=)
PL (7) PL3348264T3 (https=)
PT (7) PT2616069T (https=)
RU (4) RU2013116405A (https=)
SG (4) SG188571A1 (https=)
SI (5) SI3348264T1 (https=)
TR (1) TR201909249T4 (https=)
TW (4) TW201240661A (https=)
UA (1) UA112973C2 (https=)
WO (4) WO2012037453A1 (https=)
ZA (4) ZA201302193B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190022895A (ko) * 2010-09-16 2019-03-06 알러간, 인코포레이티드 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241553B1 (en) * 2009-02-13 2019-04-10 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
EP2782569A1 (en) 2011-11-21 2014-10-01 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
JP7584802B2 (ja) * 2018-08-24 2024-11-18 アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｓｔｉｎｇタンパク質アゴニスト
WO2022221071A1 (en) * 2021-04-16 2022-10-20 Ads Therapeutics Llc Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision
WO2025179071A1 (en) * 2024-02-20 2025-08-28 Bausch + Lomb Ireland Limited Sustained-release drug delivery compositions for treating ocular diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036480A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
WO2009089132A1 (en) 2008-01-09 2009-07-16 Allergan, Inc. Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
WO2010091209A1 (en) 2009-02-06 2010-08-12 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
WO2010093930A1 (en) * 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69307505T2 (de) 1992-05-13 1997-07-24 Sandoz-Patent-Gmbh, 79539 Loerrach Opthalmische zusammensetzungen enthaltend ein cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
MXPA05012679A (es) * 2003-05-27 2006-02-08 Sod Conseils Rech Applic Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20060209374A1 (en) * 2003-07-14 2006-09-21 Koninklijke Philips Electronics N.V. Projection device
MXPA06002716A (es) * 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP4955543B2 (ja) 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036480A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
WO2009089132A1 (en) 2008-01-09 2009-07-16 Allergan, Inc. Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
WO2010091209A1 (en) 2009-02-06 2010-08-12 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
WO2010093930A1 (en) * 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190022895A (ko) * 2010-09-16 2019-03-06 알러간, 인코포레이티드 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR102104760B1 (ko) * 2010-09-16 2020-04-27 알러간, 인코포레이티드 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR20200044147A (ko) * 2010-09-16 2020-04-28 알러간, 인코포레이티드 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR20200091507A (ko) * 2010-09-16 2020-07-30 알러간, 인코포레이티드 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR102139905B1 (ko) 2010-09-16 2020-07-31 알러간, 인코포레이티드 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
KR102354097B1 (ko) * 2010-09-16 2022-01-20 알러간, 인코포레이티드 [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그

Also Published As

Publication number Publication date
IL225278A (en) 2015-11-30
WO2012037490A1 (en) 2012-03-22
CL2013000734A1 (es) 2013-11-08
TW201240662A (en) 2012-10-16
UA112973C2 (uk) 2016-11-25
AU2011301901B2 (en) 2016-02-11
PT2616068T (pt) 2016-09-13
CN103221045A (zh) 2013-07-24
EP2616069A1 (en) 2013-07-24
CL2013000736A1 (es) 2013-07-12
CA2812197C (en) 2024-01-02
CA2812191A1 (en) 2012-03-22
US20130289088A1 (en) 2013-10-31
AU2011301932B2 (en) 2016-02-25
US8492422B2 (en) 2013-07-23
BR112013006352A2 (pt) 2016-06-28
PL3348264T3 (pl) 2020-08-24
US20120136036A1 (en) 2012-05-31
EP3338777B1 (en) 2020-02-05
EP3050563B1 (en) 2018-05-09
DK2616069T3 (en) 2016-12-19
AU2011301856A1 (en) 2013-05-02
US20160354346A1 (en) 2016-12-08
EP2616067A1 (en) 2013-07-24
US20140057958A1 (en) 2014-02-27
CN103200941A (zh) 2013-07-10
RU2013116405A (ru) 2014-10-27
IL225280A0 (en) 2013-06-27
PL2616069T3 (pl) 2017-04-28
PL2616068T3 (pl) 2016-11-30
HUE047476T2 (hu) 2020-04-28
DK3338777T3 (da) 2020-04-20
MY191369A (en) 2022-06-20
HUE038698T2 (hu) 2018-11-28
HK1185538A1 (zh) 2014-02-21
EP3050564B1 (en) 2019-09-04
CA3077732A1 (en) 2012-03-22
PL3338777T3 (pl) 2020-07-13
MY168763A (en) 2018-12-04
MX2013003002A (es) 2013-06-28
EP3636263B1 (en) 2021-11-03
EP3053576A1 (en) 2016-08-10
HK1185541A1 (zh) 2014-02-21
TWI591058B (zh) 2017-07-11
EP3050564A1 (en) 2016-08-03
RU2612351C2 (ru) 2017-03-07
US8492557B2 (en) 2013-07-23
EP2616068A1 (en) 2013-07-24
BR112013006320A2 (pt) 2016-06-21
AU2011301932C1 (en) 2016-09-01
CN103200941B (zh) 2015-12-16
CN103200942A (zh) 2013-07-10
PT2616069T (pt) 2016-12-06
SG188572A1 (en) 2013-04-30
ES2760920T3 (es) 2020-05-18
WO2012037484A1 (en) 2012-03-22
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
PT3053576T (pt) 2018-10-08
AR083019A1 (es) 2013-01-23
KR20190022895A (ko) 2019-03-06
ES2788051T3 (es) 2020-10-20
EP3078376B1 (en) 2019-03-27
HK1257416A1 (en) 2019-10-18
ZA201302288B (en) 2013-11-27
US20150148394A1 (en) 2015-05-28
JP6045495B2 (ja) 2016-12-14
DK3050563T3 (en) 2018-08-13
MX2013003008A (es) 2013-06-28
PL3050564T3 (pl) 2020-06-01
KR102354097B1 (ko) 2022-01-20
SG188571A1 (en) 2013-04-30
DK3050564T3 (da) 2019-11-25
US20130296394A1 (en) 2013-11-07
SI3050563T1 (sl) 2018-10-30
SI3050564T1 (sl) 2020-02-28
AU2011301932A1 (en) 2013-05-02
KR20130114140A (ko) 2013-10-16
JP6073229B2 (ja) 2017-02-01
KR20200044147A (ko) 2020-04-28
CN103209694A (zh) 2013-07-17
EP2616068B1 (en) 2016-07-13
HK1185540A1 (en) 2014-02-21
DK3078376T3 (da) 2019-06-24
CA2812191C (en) 2021-04-13
EP3636263A1 (en) 2020-04-15
US8853251B2 (en) 2014-10-07
CY1121024T1 (el) 2019-12-11
HUE049573T2 (hu) 2020-10-28
MX2013003009A (es) 2013-06-28
PL3053576T3 (pl) 2018-11-30
SG188570A1 (en) 2013-04-30
EP3053576B1 (en) 2018-05-16
TW201305117A (zh) 2013-02-01
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
KR20140003407A (ko) 2014-01-09
CA2812195A1 (en) 2012-03-22
KR101840501B1 (ko) 2018-05-04
US8653123B2 (en) 2014-02-18
KR102104760B1 (ko) 2020-04-27
CL2013000733A1 (es) 2013-08-23
ES2781681T3 (es) 2020-09-04
US20120149746A1 (en) 2012-06-14
ZA201302194B (en) 2013-11-27
EP2616066A1 (en) 2013-07-24
AU2011301847B2 (en) 2016-02-11
US8501796B2 (en) 2013-08-06
SI3348264T1 (sl) 2020-07-31
AU2011301847A1 (en) 2013-05-02
EP2616067B1 (en) 2016-05-18
HUE048725T2 (hu) 2020-09-28
ES2593612T3 (es) 2016-12-12
BR112013006355A2 (pt) 2016-06-28
WO2012037499A1 (en) 2012-03-22
DK3348264T3 (da) 2020-03-23
HUE039090T2 (hu) 2018-12-28
PT3338777T (pt) 2020-05-06
SI3053576T1 (sl) 2018-11-30
EP3659600A1 (en) 2020-06-03
EP3338777A1 (en) 2018-06-27
AR083018A1 (es) 2013-01-23
MY161607A (en) 2017-04-28
SG188573A1 (en) 2013-04-30
BR112013006320B1 (pt) 2022-08-30
EP2616066B1 (en) 2016-07-13
AU2011301856C1 (en) 2016-09-08
KR101840500B1 (ko) 2018-03-20
CA2811559A1 (en) 2012-03-22
RU2013116403A (ru) 2014-10-27
CN105412092B (zh) 2020-11-17
TW201305116A (zh) 2013-02-01
EP3050563A1 (en) 2016-08-03
CN105412092A (zh) 2016-03-23
PT3050563T (pt) 2018-10-01
PT3050564T (pt) 2019-12-11
CL2013000735A1 (es) 2013-11-29
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
CY1122958T1 (el) 2021-10-29
RU2013116541A (ru) 2014-10-27
CA3079450A1 (en) 2012-03-22
EP3078376A1 (en) 2016-10-12
KR20200091507A (ko) 2020-07-30
US20120142746A1 (en) 2012-06-07
ZA201302193B (en) 2013-11-27
ES2687420T3 (es) 2018-10-25
CA2812197A1 (en) 2012-03-22
PL3050563T3 (pl) 2018-12-31
EP3348264A1 (en) 2018-07-18
WO2012037453A1 (en) 2012-03-22
JP2013540749A (ja) 2013-11-07
JP2013537236A (ja) 2013-09-30
PT3348264T (pt) 2020-04-02
MY173846A (en) 2020-02-24
KR102139905B1 (ko) 2020-07-31
DK3053576T3 (en) 2018-08-20
IL225282A0 (en) 2013-06-27
AU2011301901A1 (en) 2013-05-02
EP3348264B1 (en) 2020-01-01
ES2737230T3 (es) 2020-01-10
TW201240661A (en) 2012-10-16
ES2904479T3 (es) 2022-04-05
JP2013541527A (ja) 2013-11-14
US20120122945A1 (en) 2012-05-17
HK1185539A1 (zh) 2014-02-21
NZ608751A (en) 2015-04-24
SI3338777T1 (sl) 2020-08-31
ES2684055T3 (es) 2018-10-01
MX2013003004A (es) 2013-06-28
AR083020A1 (es) 2013-01-23
DK2616068T3 (en) 2016-08-29
CA3122745A1 (en) 2012-03-22
DK3636263T3 (da) 2022-01-10
IL225278A0 (en) 2013-06-27
EP3698789A1 (en) 2020-08-26
ES2607084T3 (es) 2017-03-29
TR201909249T4 (tr) 2019-07-22
CY1122809T1 (el) 2021-05-05
ES2613509T3 (es) 2017-05-24
EP2616069B1 (en) 2016-11-16
IL225281A0 (en) 2013-06-27
JP2013537237A (ja) 2013-09-30
CA3116249A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
KR101952457B1 (ko) [3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐] 메탄올의 에스테르 프로드러그
AU2011301856B2 (en) Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
HK40028884A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl] methanol
HK40028884B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl] methanol
HK40036790A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
HK1185540B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130415

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160907

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180327

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180811

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180327

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180811

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180523

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20181121

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20181107

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180811

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20180523

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190219

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190220

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190220

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20211229

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240102

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 7

End annual number: 7